Suzhou, China, February 2th, 2026—CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that a meeting of the Board will be held on Thursday, March 26, 2026, for the purposes of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and its publication.

Following the Board meeting, the Company will issue a voluntary announcement on March 26, 2026, and host an investor conference call on March 27, 2026. These communications will provide shareholders and potential investors with the latest business developments, including updates on the following key areas:

• CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody): Updates on Phase I clinical data, progress of the Phase II trial, and business development (BD) advancements;
• CS5001 (ROR1 ADC): Recent clinical trial progress and development updates;
• Sugemalimab (anti-PD-L1 antibody): Updates on global commercialization progress;
• GAVRETO^® (pralsetinib): Sales performance updates following its inclusion in China's National Reimbursement Drug List (NRDL), effective January 1, 2026; and
• Preclinical pipeline and Investigational New Drug (IND) plans: Development progress and plans for IND applications.

Further details regarding the agenda and arrangements for the investor conference call will be provided in due course.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

IR contact: ir@cstonepharma.com

PR contact: pr@cstonepharma.com

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.